effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancersa phase 1/2 single-group open-label trial
effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers<br>a phase 1/2 single-group open-label trial
effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancersa phase 1/2 single-group open-label trial<br>